PhaseⅡtrial of carboplatin/docetaxel in patients with resected NSCLC

• 作者: Akihiko Uchiyama Fumihiro Tanaka Hidetaka Uramoto Masaaki Inoue Masakazu Sugaya Noriyuki Ebi Ryoichi Nakanishi Takeshi Hanagiri Teruo Iwata
• 来源期刊: 世界呼吸病学杂志
• 学科: 医学
• 关键词: NON-SMALL cell lung cancer ADJUVANT chemotherapy CARBOPLATIN DOCETAXEL Treatment COMPLIANCE Surgical RESECTION
• 年，卷（期）: 2014,（1）
• 页码范围: 1-7
• 页数: 7页
• 分类号: R735.3

摘要

AIM:To investigate the development of a safer chemotherapeutic regimen with better compliance,a total of 67 patients were enrolled as a single arm in a twostage multi-center phaseⅡstudy.METHODS:The patients received chemotherapy with carboplatin(CBDCA)with an area under the curve(AUC)of 5,and docetaxel(DTX)at 60 mg/m2 tri-weekly for three cycles after surgery.The primary endpoint of this study was compliance,while the secondary endpoints were the adverse events(AE)and recurrencefree survival(RFS).RESULTS:Sixty-one patients were treated in this study arm.The patients were 43 males and 18 females,with a median age of 64.6 years.Fifty-one patients(83.6%)completed all three cycles of therapy.The presence of Grade 3 and 4 neutropenia was noted in 25%and 66%of the patients,respectively.The non-hematological AE were less frequently reported,and no treatmentrelated death was registered.The two-year RFS and OS rates of the 61 patients were 69.8%and 88.3%,respectively.CONCLUSION:A tri-weekly schedule of CBDCA and DTX as adjuvant chemotherapy showed a favorable feasibility.